Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by American Century Companies Inc.

American Century Companies Inc. grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,604,024 shares of the biopharmaceutical company’s stock after acquiring an additional 11,291 shares during the quarter. American Century Companies Inc.’s holdings in Alnylam Pharmaceuticals were worth $377,443,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ALNY. Larson Financial Group LLC increased its stake in shares of Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 73 shares during the last quarter. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $33,000. OFI Invest Asset Management acquired a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $35,000. True Wealth Design LLC increased its position in shares of Alnylam Pharmaceuticals by 15,300.0% during the 3rd quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 153 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $45,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on ALNY. Wells Fargo & Company raised their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research report on Friday. Scotiabank raised their price objective on Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the stock a “sector outperform” rating in a research report on Friday. Citigroup raised their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a research report on Friday. HC Wainwright raised their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. Finally, Needham & Company LLC restated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $310.22.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $283.34 on Friday. The stock has a 50-day simple moving average of $257.16 and a 200-day simple moving average of $259.65. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The stock has a market capitalization of $36.68 billion, a PE ratio of -130.57 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.